Researchers have identified a promising new antibody that can help patients with aggressive and metastatic anal cancer. The findings of the first clinical trial for metastatic patients showed that the treatment with antibody nivolumab -- one of the drugs represented among the growing arsenal of immunotherapy therapies -- may help a majority of patients with squamous cell carcinoma of the anal canal (SCCA). Metastatic SCCA a cancer often associated with human papillomavirus (HPV) infection is normally treated with chemotherapy. However treatment with nivolumab freed the immune system to attack cancer by disrupting a brake that halts immune response and showed
